(Medscape Medical News) Oct 4, 2017 - Obinutuzumab for induction and maintenance provides significantly higher PFS than rituximab, the current standard of care for follicular lymphoma (FL). But an editorial cautions it's too soon to tell.
Read Article
Dean Gesme, MD (Posted: October 05, 2017)
An excellent editorial this past week in JCO authored by Jim Armitage and Dan Longo on this important topic.
Professor of Medicine, Division of Hematology/Medical O...
Professor and Director, Division of Hematology Oncology...
Follow @OBRTweets